We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Evolus, Inc.
Health Care · Pharmaceuticals
Structural: pure-play aesthetic injectables challenger in a duopoly long held by $ABBV Botox + Juvederm and $RVNC Daxxify. Jeuveau is the #2 US neurotoxin by share among new accounts; Evolysse adds a second leg (HA fillers) into a ~$2B US category where AbbVie owns ~70% share.
Asset-light commercial model - manufacturing outsourced to Daewoong (toxin) and Symatese (fillers), Evolus runs sales force + brand.
(1) Jeuveau share gains accelerating in cash-pay aesthetic channel insulated from PBMs / Medicare; (2) Evolysse launch doubles addressable revenue per practice without new sales infrastructure; (3) operating leverage - gross margin ~70%, SG&A largely fixed, every incremental dollar drops; (4) international expansion (EU, Canada, Australia) still early; (5) $ABBV Botox patent expirations + biosimilar pressure could compress incumbent pricing power.
(1) discretionary cash-pay demand cyclical - recession shrinks aesthetic spend before staples; (2) Daewoong arbitration history and Medytox trade-secret litigation overhang; (3) Revance ($RVNC) Daxxify + Galderma Relfydess crowding the long-duration toxin niche; (4) Evolysse launch execution risk vs entrenched Juvederm injector loyalty; (5) cash burn - has run at operating loss, dilution risk if scale curve slips; (6) single-source supplier concentration on both product lines.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.